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D uctal carcinoma in situ (DCIS) of the breast is defined as malignant cells localized in ducts 
without evidence of invasion through the basement 
membrane.  Since the development of a screening sys-
tem,  the incidence of DCIS has increased [1 , 2],  and 
the development of percutaneous core needle biopsy 
(CNB) technology has increased the number of individ-
uals preoperatively diagnosed with DCIS (abbreviated 
as CNBDCIS) without incisional biopsy.  Surgery is 
fundamental to the successful treatment of patients with 
CNBDCIS [3],  but there are two main challenges con-
cerning the surgical treatment of CNBDCIS.  The first is 
the possibility of coexisting invasive ductal cancer 
(IDC),  which can lead to the underestimation of DCIS 
by CNB,  and the second is obtaining a safe surgical 
margin,  especially in conservative breast surgery.
A number of reports,  including a meta-analysis,  
have described the clinical and pathological factors 
contributing to the underestimation of CNBDCIS 
[3-10].  There are also numerous reports on the difficul-
ties of obtaining positive margins [11-18].  Surgeons 
should have a good understanding of these problems in 
order to provide the optimal treatment of patients with 
CNBDCIS.
Microcalcifications observed on mammography 
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To clarify the surgical outcomes of breast cancer patients with a preoperative diagnosis of ductal carcinoma in 
situ (DCIS) by core needle biopsy (CNB) (abbreviated as CNBDCIS),  we retrospectively analyzed the cases of 
131 patients with CNBDCIS who underwent surgery at Oomoto Hospital (32 total mastectomies,  99 conserva-
tive mastectomies).  Our analysis of underestimation and predictors of invasive breast cancer of CNBDCIS 
revealed that the underestimation rate of CNBDCIS was 40.5% (53/131).  A logistic regression analysis revealed 
that palpable tumors (yes to no,  odds ratio [OR] 3.25),  mammography (MMG) category group (category 4 or 5 
to categories 1 , 2,  or 3,  OR 4.69) and MMG microcalcifications (no to yes,  OR 0.24) were significant predictive 
factors for CNBDCIS invasion.  In our analysis of the predictors of positive margins during CNBDCIS surgery,  
36 (27.5%) of the 131 patients had positive margins after postoperative pathological examination.  A logistic 
regression analysis revealed that the operative procedure (conservative surgery to total mastectomy,  OR 21.4) 
and MMG microcalcifications (yes to no,  OR 3.35) were significant factors related to positive margins during 
CNBDCIS surgery.  Thus,  MMG microcalcifications are a negative predictor of upgrading of CNBDCIS and a 
positive predictor of positive surgical margins for CNBDCIS.
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(MMG) are commonly detected in patients with DCIS 
or IDC,  but the relationships between MMG microcal-
cifications and the underestimation of DCIS or positive 
surgical margins in CNBDCIS have not been sufficiently 
examined.  In the present study,  we evaluated the sig-
nificance of microcalcifications on MMG in relation to 
the above two problems.
Patients and Methods
Of the 3,020 patients who underwent a CNB at 
Oomoto Hospital (No. 0111442) between January 2008 
and June 2018,  the 131 patients with a preoperative 
diagnosis of CNBDCIS who underwent surgery at the 
same hospital were enrolled in this study.  Secondary 
breast cancer patients who had undergone a prior par-
tial mastectomy of the ipsilateral breast were excluded.  
The indication for a CNB at our hospital is suspicion of 
malignant tumor by mammography or ultrasound 
(including only calcification on mammography if 
malignancy is suspected).
Mammography was performed in mediolateral 
oblique (MLO) and craniocaudal (CC) views using the 
mammography machines MGU-100B Mammorex 
(Toshiba,  Tokyo).  After April 2013,  mammography 
was performed using a Peruru MGU1000D digital 
mammography system (Toshiba).
The mammography findings were analyzed accord-
ing to the Mammography Guidelines (3rd edition) 
issued by the Japan Radiological Society [19].  In the 
present study,  we defined microcalcifications on MMG 
as positive based on their distribution (segmental,  lin-
ear,  and grouped or clustered) and shape (small round 
calcifications,  fine,  branching calcifications,  or casting 
calcifications).  The microcalcifications ranged in size 
from 0.5 mm to 3 mm and were produced in the tumor.  
Obvious calcifications caused by benign lesions were 
excluded.
Ultrasound (US) was performed using a US Xario 
SSA-660A 8 MHz or Aplio XG SSA-790A 12 MHz 
(Toshiba).  The findings were analyzed according to the 
Guidelines for Breast Ultrasound-Management and 
Diagnosis (3rd edition) issued by the Japan Association 
of Breast and Thyroid Sonology [20].  All of the mam-
mography findings and US findings were evaluated by 
surgeons,  including laboratory technicians for US 
examinations,  who were qualified by The Japan Central 
Organization on the Quality Assurance of Breast Cancer 
Screening.  The preoperative tumor size was measured 
by MMG or US,  whichever depicted the tumor size 
more clearly.
The US-guided CNB was performed on all patients 
by surgeons.  In 122 patients,  a 14-gauge core tissue 
biopsy needle (Bard Magnum; Bard,  Crawley,  UK) was 
used,  and in the other 9 patients,  a 10-gauge vacuum- 
assisted biopsy system (Vacora; Bard) was used.  The 
average number of cores was 2.9 (2-6).
Regarding the positive margins,  pathological exam-
inations were carried out using paraffin sections and 
hematoxylin-eosin staining.  After formalin fixation for 
1-2 days,  all specimens were cut perpendicularly at 
5-mm intervals for the 99 conservative surgeries and 9 
of the 32 total mastectomies.  For the remaining 22 total 
mastectomy specimens,  3-5 cuts were made for the 
pathological examination of the tumor and margins.  
The definitive (postoperative) size of the tumor was 
measured pathologically.  The margins were considered 
positive when cancer cells were detected within 2 mm 
of the lateral edges or skin side of the specimen except 
for the bottom side (chest wall side).
All statistical analyses were performed using EZR 
(Saitama Medical Center,  Jichi Medical University,  
Saitama,  Japan),  which is a graphical user interface for 
R (The R Foundation for Statistical Computing,  
Vienna,  Austria) [21].  More precisely,  it is a modified 
version of R Commander designed to add statistical 
functions frequently used in biostatistics.  In general,  
p-values < 0.05 by Fisher’s exact test,  logistic regression,  
or the unpaired t-test were considered significant.  This 
study was approved by the ethics committee of Oomoto 
Hospital in accordance with the ethical standards laid 
down in the 1964 Declaration of Helsinki and all subse-
quent revisions.
Results
All 131 patients were females,  with an average age 
of 59.5 years old (35-90 years).  Total mastectomy was 
performed for 32 patients,  and conservative mastec-
tomy was performed for 99 patients (87 partial mastec-
tomies,  5 skin-sparing mastectomies,  and 7 nipple- 
sparing mastectomies).
In all 25 patients with only microcalcifications on 
MMG who underwent a partial mastectomy,  mam-
mography of the specimen was done to verify the com-
plete resection of the lesion with microcalcifications.
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Ninety-five patients underwent a sentinel node 
biopsy (SLNB),  and 30 patients underwent an axillary 
node dissection (ALND).  Among the 30 patients with 
ALND (20 total mastectomies and 10 conservative sur-
geries),  2 had preoperative axillary lymph node swell-
ing,  and 1 patient underwent an ALND due to positive 
sentinel node metastasis on a frozen section.  Seven 
patients had lymph node metastasis.  One of the 14 
patients with ductal carcinoma in situ with minimal 
invasion (DCISM) and 6 of the 29 patients with invasive 
ductal carcinoma (IDC) had lymph node metastases.  
As a result,  the rate of lymph node metastasis was 5.3% 
among the 131 CNBDCIS patients.
Analysis of underestimation and predictors of inva-
sive breast cancer in CNBDCIS. The results of the 
univariate analysis (Fisher’s exact test) of the clinico-
pathological factors for CNBDCIS in relation to inva-
sion are presented in Table 1.  MMG findings are pre-
sented based on the categories described by 
Wiratkapun et al.  [8].  Among the 45 patients with only 
microcalcifications on mammography,  the MMG cate-
gory was 3 in 17 patients,  category 4 in 9 patients,  and 
category 5 in 19 patients.
The rate of underestimation of CNBDCIS was 40.5% 
(53/131).  The five factors that were significantly related 
to invasion by CNBDCIS were as follows: palpable 
tumor,  MMG category group 4-5,  MMG microcalcifi-
cations,  MMG mass,  and US category 4-5.  Patient age,  
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Table 1　 Clinicopathological factors of the patients with a preoperative diagnosis of DCIS by CNB related to tumor invasion
Tumor invasion
Factor Group DCIS DCISM (15)+ IDC (38) p-value
n 78 53
Sex Female 78 (100.0) 53 (100.0) NA
Age ＜60 44 (57.1) 21 (39.6) 0.074
≧60 33 (42.9) 32 (60.4)
Site Left 42 (53.8) 21 (39.6) 0.154
Right 36 (46.2) 32 (60.4)
Palpable tumor (%) No 43 (55.8) 10 (18.9) ＜0.001
Yes 34 (44.2) 43 (81.1)
MMG ﬁndings (%) Microcalciﬁcations 36 (46.2)  9 (17.0)
Mass 21 (26.9) 28 (52.8)
Mass with microcalciﬁcations 10 (12.8)  7 (13.2)
Asymmetrical density 5 (6.4) 1 (1.9)
Architectural distortion 1 (1.3) 5 (9.4)
Invisible on mammogram 5 (6.4) 3 (5.7)
MMG category group (%) 1,  2,  3 43 (55.1) 15 (28.3) 0.004
4,  5 35 (44.9) 38 (71.7)
MMG microcalciﬁcations (%) No 32 (41.0) 37 (69.8) 0.001
Yes 46 (59.0) 16 (30.2)
MMG mass (%) No 47 (60.3) 18 (34.0) 0.004
Yes 31 (39.7) 35 (66.0)
US category (%) 2,  3 30 (38.5) 8 (15.1) 0.006
4,  5 48 (61.5) 45 (84.9)
CNB nuclear grade (%) Low 36 (46.2) 34 (65.4) 0.087
Intermediate 30 (38.5) 14 (26.9)
High 12 (15.4) 4 (7.7)
Comedo necrosis No 55 (70.5) 45 (84.9) 0.063
Yes 23 (29.5) 8 (15.1)
ERPgR (%) Negative 25 (32.1) 11 (20.8) 0.169
Positive 53 (67.9) 42 (79.2)
Preoperative size Mean (sd)　cm 2.63 (1.68) 2.68 (1.75) 0.856
CNB,  core needle biopsy; DCIS,  ductal carcinoma in situ; DCISM,  ductal carcinoma in situ with microinvasion; IDC,  invasive ductal 
carcinoma.
CNB nuclear grade,  comedo necrosis,  ERPgR status,  
and preoperative size (unpaired t-test) were not signifi-
cantly related to invasion by CNBDCIS.
The logistic regression analysis (backward stepwise 
selection) showed that the following were significant 
predictive factors of invasion by CNBDCIS: palpable 
tumor (yes to no,  OR 3.25),  MMG category group (cat-
egory 4 or 5 to categories 1 , 2,  or 3,  OR 4.69) and 
MMG microcalcifications (no to yes,  OR 0.24) (Table 
2).
Analysis of the predictors of positive surgical mar-
gins for CNBDCIS. Thirty-six (27.5%) of the 131 
CNBDCIS patients had positive margins after a postop-
erative pathological examination.  The results of our 
univariate analysis (Fisher’s exact test) of the clinico-
pathological factors of CNBDCIS related to positive 
surgical margins are presented in Table 3.  Palpable 
tumor,  MMG microcalcifications,  MMG mass,  and the 
operative procedure were significantly related to posi-
tive surgical margins for CNBDCIS.  Patient age,  MMG 
category group,  tumor invasion,  CNB nuclear grade,  
and preoperative size (unpaired t-test) were not signifi-
cantly related to positive surgical margins for 
CNBDCIS.
The logistic regression analysis (backward stepwise 
selection) revealed that the operative procedure (con-
servative surgery to total mastectomy,  OR 21.4) and 
MMG microcalcifications (yes to no,  OR 3.35) were the 
significant factors related to positive surgical margins 
for CNBDCIS (Table 4A).  The logistic regression anal-
ysis (backward stepwise selection) in conservative sur-
gery revealed that MMG microcalcifications (yes to no,  
OR 3.23) was the only significant factor related to posi-
tive surgical margins for CNBDCIS (Table 4B).  The 
rate of positive margins with MMG microcalcifications 
in conservative surgery was 50% (22/44),  and that with-
out MMG microcalcifications was 24% (13/55).
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Table 2　 Logistic regression analysis for CNBDCIS tumor inva-
sion
Factor Odds ratio p-value
(Intercept) 0.244 (0.0951-0.625) 0.00329
Palpable tumor 3.250 (1.3200-7.970) 0.0102
MMG category group 4.690 (1.8300-12.000) 0.00131
MMG microcalciﬁcations 0.239 (0.0923-0.620) 0.00325
Table 3　 Clinicopathological factors related to positive margins
Positive margin
Factor Group No Yes p-value
n 95 36
Palpable tumor (%) No 31 (33.0) 22 (61.1) 0.005
Yes 63 (67.0) 14 (38.9)
MMG category group (%) 1,  2,  3 40 (42.1) 18 (50.0) 0.437
4,  5 55 (57.9) 18 (50.0)
MMG microcalciﬁcations (%) No 56 (58.9) 13 (36.1) 0.03
Yes 39 (41.1) 23 (63.9)
MMG mass (%) No 41 (43.2) 24 (66.7) 0.019
Yes 54 (56.8) 12 (33.3)
US category group (%) 2,  3 25 (26.3) 13 (36.1) 0.287
4,  5 70 (73.7) 23 (63.9)
Operative procedure (%) 1. Partial mastectomy 61 (64.2) 26 (72.2)
2. Total mastectomy 31 (32.6) 1 (2.8)
3. Skin sparing mastectomy 1 (1.1) 4 (11.1)
4. Nipple sparing mastectomy 2 (2.1) 5 (13.9)
Operative procedure group (%) 2 31 (32.6) 1 (2.8) ＜0.001
1,  3,  4 64 (67.4) 35 (97.2)
Invasion (%) DCIS 53 (55.8) 25 (69.4) 0.169
DCISM (15)+ IDC (38) 42 (44.2) 11 (30.6)
CNB nuclear grade (%) Low 55 (58.5) 15 (41.7) 0.141
Intermediate 27 (28.7) 17 (47.2)
High 12 (12.8) 4 (11.1)
Preoperative size Mean (sd)　cm 2.56 (1.63) 2.90 (1.89) 0.302
In the 44 conservative surgeries of patients with 
MMG microcalcifications,  the post- to pre-operative 
size difference (pathological definitive size-preoperative 
size) in the margin-positive group (1.24 cm) was sig-
nificantly larger than that in the margin-negative group 
(0.34 cm) (Fig. 1).
Discussion
In a study using resected specimens,  the incidence 
of CNBDCIS being upgraded to invasive cancer after 
pathological examination was 0% to 59% [3].  The clin-
ical predictors of such upgrade are as follows: larger 
tumor [3 , 5 , 6],  palpable mass [3 , 5],  mass on mam-
mography [3 , 4],  Breast Imaging Reporting and Data 
System (BI-RADS) category 4 or 5 [3 , 5],  biopsy device 
[3 , 5],  nuclear grade at CNB [3 , 5 , 7 , 8],  comedo 
necrosis at CNB [8 , 9],  and overexpression of human 
epidermal growth factor 2 (HER2) [10].
In the present study,  the logistic regression analysis 
demonstrated palpable mass (yes to no),  MMG cate-
gory (4 or 5 to 1 , 2 or 3) and MMG microcalcifications 
(no to yes) to be predictors of an upgrade.  Although 
these findings concerning palpable mass and MMG 
category (similar to BI-RADS category) are consistent 
with previous reports,  the other factors are not.  First,  
the preoperative size of DCIS and that of the upgraded 
tumors were similar in our series.  Nuclear grade and 
comedo necrosis at CNB were not related to upgrading,  
provided that comedo necrosis was not significant on 
meta- analysis.  Among the above underestimation pre-
dictors,  a large vacuum-assisted stereo-guided CNB can 
provide a more accurate diagnosis with a lower rate of 
underestimation.  In our series,  all CNB procedures 
were performed under US,  and a vacuum-assisted 
biopsy (VAB) was used only for lesions with microcal-
cifications without a mass.  As a result,  the rate of 
underestimation by VAB was 11.1% (1/9).  However,  a 
case selection bias may have been present.
MMG microcalcifications were a negative predictor 
of upgraded CNBDCIS in the present study.  The 
underestimation rate of CNBDCIS with MMG micro-
calcifications was 25.8% (16/62),  and that without 
MMG microcalcifications was 53.6% (37/69).  In a large 
series (506 cases of CNBDCIS) evaluated by Kim et al.  
[5],  the underestimation rate of CNBDCIS with MMG 
microcalcifications (33.9%) was significantly lower than 
that without MMG microcalcifications (66.1%) by uni-
variate analysis (p < 0.001).  Their report is consistent 
with ours.  The meta-analysis also revealed that the 
mammographic mass (vs. calcification only) is signifi-
cantly associated with upgraded invasion by CNBDCIS 
[3].
On the other hand,  in the report by Miyake et al.  [6] 
microcalcification was not a predictive factor of invasive 
cancer.  Houssami et al.  [7] found that the size of micro-
calcifications on imaging was significantly related to 
invasive breast cancer in women with newly diagnosed 
DCIS on vacuum-assisted CNB.  Thus,  MMG micro-
calcifications and the upgrading of CNBDCIS should be 
further investigated.  It is notable that masses with 
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Table 4A　 Logistic regression analysis for positive margins
Factor Odds ratio p-value
(Intercept) 0.0142 (0.00171-0.118) 0.0000815
MMG microcalciﬁcations 3.3500 (1.43000-7.820) 0.00527
Operative procedure group 21.4000 (2.72000-168.000) 0.00358
Table 4B　 Logistic regression analysis for positive margins in 
conservative surgery
Factor Odds ratio p-value
(Intercept) 0.31 (0.166-0.577) 0.00022































Fig. 1　 Post － preoperative size diﬀerences (pathological deﬁni-
tive size － preoperative size) in conservative surgeries for patients 
with MMG microcalciﬁcations.
microcalcifications have a high upgrade rate (41%,  
7/17).  Wiratkapun et al.  [8] reported that the upstaging 
rate of masses with calcification was as high as 66% 
(25/38).
Regarding positive surgical margins,  although con-
servative breast surgery for DCIS is widely accepted as a 
surgical treatment [1 , 2 , 22],  positive surgical margins 
are highly correlated with the local recurrence of breast 
cancer [11-13].  Hassan et al.  [18] reported that among 
249 patients,  positive margins were identified in 104 
(41.8%),  with a positive rate of 25% in 125 mastecto-
mies and 59% in 124 conservative surgeries.  In the 
present study,  27.5% of the 131 patients and 35.3% of 
the 99 conservative surgeries had positive margins.  
Although only 9 of 31 mastectomies were examined 
using 5-mm serial sections in this study,  the rate of 
positive margins in conservative surgery may be consis-
tent with previous reports.  Lesions that were ≥ 1.55 cm 
in size were reported to have a relative risk of positive 
margins.  The clinicopathological factors related to pos-
itive margins were larger-sized DCIS on mammograms 
[15-17],  the volume of the resected specimen [17],  and 
high-grade [15] or low-grade DCIS [14].  Several stud-
ies of DCIS demonstrated that the margin-positive 
resection rates were 30-60% in conservative surgery 
[14-18].
Although radiation therapy after conservative sur-
gery can control local recurrence in margin-positive 
patients [23-25],  a margin-free surgical outcome is 
desired.  Previous investigations found no relationship 
between MMG microcalcifications and positive mar-
gins.  In one DCIS study,  the rates of microcalcifica-
tions were 70-90% [14-16].  In the present study,  DCIS 
and IDC of CNBDCIS were included,  and the overall 
rate of MMG microcalcifications was 47.3%.  In the 
conservative surgeries,  the positive margin rate in the 
patients with MMG microcalcifications was 50%,  and 
the corresponding rate in the patients without MMG 
microcalcifications was 24%.
Based on the results of the logistic regression analy-
sis,  MMG microcalcifications had the strongest rela-
tionship with positive margins.  Moreover,  although 
there was no significant difference in preoperative 
tumor size between our margin-positive and-negative 
groups,  the post-preoperative size differences in the 
margin-positive group (1.24 cm) were significantly 
larger than those in the margin-negative group (0.34 cm) 
in conservative surgery for the patients with MMG 
microcalcifications.  This phenomenon may be 
explained by the fact that small DCIS ducts without 
calcification are commonly seen at the edges of DCIS 
tumors with microcalcifications without a mass.  
Therefore,  a larger stump should be taken in patients 
with MMG microcalcifications who undergo conserva-
tive surgery.
Dillon et al.  [16] reported that mammographic 
underestimation of pathological size was closely related 
to positive margins.  Unfortunately,  in the present study 
we could not detect any preoperative factor of microcal-
cifications on MMG (distribution or shape or preopera-
tive size) that was related to a positive margin.  The only 
factor related to a positive margin was the post- vs. 
pre-operative size difference.
Axillary treatment is not necessary in cases of true 
DCIS.  A routine SLNB is not required for the treatment 
of CNBDCIS after conservative surgery [26-28],  and a 
secondary SLNB is only recommended when the post-
operative pathological examination reveals invasive 
cancer.  However,  until now,  we have preferred to per-
form an SLNB for most patients with CNBDCIS 
because of the relatively high underestimation rate of 
CNBDCIS and because the lymphatic drainage may 
have changed,  resulting in an inaccurate SNLB.  
However,  based on our present findings,  for patients 
with CNBDCIS who have a low risk of tumor invasion 
(i.e.,  those with non-palpable tumors; MMG category 
1 , 2 or 3;  or MMG microcalcifications without mass),  
we intend to perform a partial mastectomy with a suffi-
cient stump―especially for patients with MMG micro-
calcifications without SLNB― in the future.
This study has some limitations.  First,  the number 
of patients was relatively small (n = 131).  Although our 
surgeons are qualified to read mammography findings 
by the Japan Central Organization on Quality 
Assurance of Breast Cancer Screening,  a radiologist did 
not participate in this study.  Thus,  there may be some 
differences in the judgment of the MMG categories.  
Moreover,  we did not separate MMG calcifications into 
categories based on the distribution or shape,  to avoid 
complexity.  We defined calcifications that were 0.5-
3 mm in size produced in the tumor as MMG microcal-
cifications.  HER2 status was not evaluated because the 
CNB specimens of only half of the patients were exam-
ined.  HER2 should be examined in a future study.
Based on the logistic regression analysis results,  the 
predictors of CNBDCIS being upgraded to invasive 
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cancer were a palpable mass (yes to no,  OR 3.25),  
MMG category (4 or 5 to 1 , 2 or 3,  OR 4.69),  and 
MMG microcalcifications (no to yes OR 0.24).  The 
predictors of positive surgical margins for CNBDCIS 
were the operative procedure (conservative surgery to 
total mastectomy,  OR 21.4) and MMG microcalcifica-
tions (yes to no,  OR 3.35).  Therefore,  MMG microcal-
cifications are a negative predictor of upgrading of 
CNBDCIS and a positive predictor of positive surgical 
margins for CNBDCIS.
Conservative surgery did not result in satisfactory 
outcomes for clear margins.  We will improve the pro-
cedure based on the present data.
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